CHI Personalized Medicine, part2


	CHI Personalized Medicine, part2


	Featured Market Research Report ---------------- Takeda Pacific features the market research report: Biomarkers, Tests and Trends for Drug R&D This 2010 report analyzes the hot global market for biomarkers and related assays or tests used in drug R&D and enabling Personalized Medicine. The market study suggests the future direction of the market for biomarkers and related '-omic' or pharmacogenomic (PGx) assays or tests used in the next round of drug R&D. The report's 5-year market forecast sizes the world market and growth rate of biomarkers and assays for drug R&D spending to 2013. This 144-page study discusses ongoing regional government initiatives that are fostering worldwide development in biomarkers and Personalized Medicine opportunities. This report includes 40 tables and 12 figures to illustrate its useful findings. $2,400 for the Single User PDF emailed version. Order Your Copy Today!


	[Rosenkrans]...drug com-panies could save up to $100's of millions per drug by incor-porating pharmaco-genomics data into trials'


	Personalized Medicine. He predicted that by 2020 it will be evidence-based and patient centric. We need to move away from sick care, Rosenkrans said. He also said a new development paradigm is needed. He believes the solution is targeted clinical trials. It is estimated that drug companies could save up to $100's of millions per drug by incorporating pharmacogenomics data into trials. Everybody responds differently to therapy so patients need access to the right therapy.